Phase 3 Trial of mRNA Vaccine and Keytruda Yields Positive Results
Vaccine targets unique tumor mutations to boost immune response post-surgery.
Stock surged 93% after trial showed superior efficacy over Keytruda alone.
Companies plan to present results at medical meeting and share with regulators.
FDA and EMA granted expedited review for the vaccine.
Personalized doses take six weeks to manufacture.
Nine additional trials explore mRNA approach for other cancers.
1 hour ago